Bob Hugin’s Celgene background highlighted in campaign materials
The passage merely outlines Hugin’s career at Celgene and his political candidacy, with no specific allegations, financial transactions, or novel connections to misconduct. It provides background cont Bob Hugin was CEO and later executive chairman of Celgene before running for U.S. Senate in New Jers Celgene’s flagship drug Revlimid generated $8.2 billion in 2017 sales. Hugin’s campaign references
Summary
The passage merely outlines Hugin’s career at Celgene and his political candidacy, with no specific allegations, financial transactions, or novel connections to misconduct. It provides background cont Bob Hugin was CEO and later executive chairman of Celgene before running for U.S. Senate in New Jers Celgene’s flagship drug Revlimid generated $8.2 billion in 2017 sales. Hugin’s campaign references
Tags
Ask AI About This Document
Extracted Text (OCR)
Technical Artifacts (8)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
twitter.com372357734460980119005762https://ir.celgene.com/presshttps://news.gallup.com/poll1/12748/business-industryhttps://www.businesswire.com/news/home/2018012https://youtu.be/K4AglRelated Documents (6)
From: jeffrey epstein <[email protected]>
Senate committee chair and ranking member lineup and potential reassignments
The passage lists current and potential future Senate committee leadership positions, but provides no concrete allegations, financial flows, or misconduct. It offers limited investigative value beyond Chairman Lisa Murkowski and Ranking Member Maria Cantwell on an unnamed committee Potential reshuffling of ranking member positions for EPW, Foreign Relations, and Appropriations Senator Jim Inhofe r
DEPARTMENT OF THE TREASURY
EFTA02722137
Celgene Settlement and New Jersey Senate Race Links to Senator Menendez
Celgene Settlement and New Jersey Senate Race Links to Senator Menendez The document references a $280 million Celgene fraud settlement and connects former pharma executive Bob Hugin, a Senate candidate, with Senator Robert Menendez. While the text is largely metadata and lacks concrete transaction details, it hints at possible political‑financial ties that merit follow‑up, especially given Menendez's recent legal scrutiny. The lead is moderately useful but not novel, as Menendez's connections to pharma have been reported before. Key insights: Celgene agreed to pay $280 M to settle fraud claims over cancer drugs (July 2017).; Bob Hugin, a former pharmaceutical executive, ran for U.S. Senate in New Jersey (Feb 2018).; Multiple New York Times articles are linked that discuss Hugin and Menendez’s Senate race.
From: Office of Terje Rod-Larsen
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.